FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002169529> ?p ?o ?g. }

• W2002169529 endingPage "45S" @default.
• W2002169529 startingPage "40S" @default.
• W2002169529 abstract "It has been 20 years since Lindstrom et al. [1] reported the results of a binding assay for acetylcholine receptor (AChR) antibodies in patients with myasthenia gravis (MG). This assay has subsequently become a major tool in evaluating patients with known or suspected MG. In the original report of Lindstrom et al., 6% of patients with generalized MG and almost 30% of those with ocular myasthenia did not have elevated binding antibody levels. In subsequent reports, from 7 to 34% of patients with MG did not have elevated binding antibodies (Table 1). These patients without elevated AChR antibodies are referred to as having seronegative myasthenia gravis (SN-MG).View this table:Table 1. Frequency of seronegative MGThe clinical features of MG patients with elevated AChR antibodies (seropositive, SP-MG) and without elevated AChR antibodies (seronegative, SN-MG) are similar, although patients with SN-MG are more likely to have purely ocular myasthenia or milder disease (Table 1). As in SP-MG, an autoimmune process underlies SN-MG. Evidence supporting this includes the fact that patients with SN-MG improve after immunotherapy such as plasma exchange, immunosuppression, and thymectomy. [2-4] Abnormal neuromuscular transmission can be transferred to animals by injecting immunoglobulin from patients with SN-MG. [5-9] This immunoglobulin has direct blocking effects on neuromuscular transmission when applied in vitro to nerve-muscle preparations. [10]Several factors may affect the frequency of SN-MG in published reports. The sensitivity of the assay has a marked effect on the proportion of patients in whom antibodies are detected. A less sensitive assay identifies fewer seropositive patients and the proportion of SN-MG is therefore greater. The duration of disease at the time the assay is performed may also influence the results. Patients may have normal AChR antibody levels within the first months of symptoms and elevated AChR antibodies thereafter (see below). Immunotherapy or thymectomy before assay …" @default.
• W2002169529 created "2016-06-24" @default.
• W2002169529 creator A5029489237 @default.
• W2002169529 creator A5053187399 @default.
• W2002169529 creator A5055671145 @default.
• W2002169529 creator A5057735384 @default.
• W2002169529 date "1997-04-01" @default.
• W2002169529 modified "2023-09-27" @default.
• W2002169529 title "Seronegative myasthenia gravis" @default.
• W2002169529 cites W1980464397 @default.
• W2002169529 cites W2007239963 @default.
• W2002169529 cites W2021879241 @default.
• W2002169529 cites W2048057683 @default.
• W2002169529 cites W2051228727 @default.
• W2002169529 cites W2100164446 @default.
• W2002169529 cites W2131575142 @default.
• W2002169529 cites W2150015810 @default.
• W2002169529 cites W2887445078 @default.
• W2002169529 doi "https://doi.org/10.1212/wnl.48.suppl_5.40s" @default.
• W2002169529 hasPublicationYear "1997" @default.
• W2002169529 type Work @default.
• W2002169529 sameAs 2002169529 @default.
• W2002169529 citedByCount "58" @default.
• W2002169529 countsByYear W20021695292013 @default.
• W2002169529 countsByYear W20021695292014 @default.
• W2002169529 countsByYear W20021695292015 @default.
• W2002169529 countsByYear W20021695292017 @default.
• W2002169529 countsByYear W20021695292018 @default.
• W2002169529 countsByYear W20021695292019 @default.
• W2002169529 countsByYear W20021695292020 @default.
• W2002169529 countsByYear W20021695292022 @default.
• W2002169529 countsByYear W20021695292023 @default.
• W2002169529 crossrefType "journal-article" @default.
• W2002169529 hasAuthorship W2002169529A5029489237 @default.
• W2002169529 hasAuthorship W2002169529A5053187399 @default.
• W2002169529 hasAuthorship W2002169529A5055671145 @default.
• W2002169529 hasAuthorship W2002169529A5057735384 @default.
• W2002169529 hasConcept C203014093 @default.
• W2002169529 hasConcept C2778105408 @default.
• W2002169529 hasConcept C71924100 @default.
• W2002169529 hasConceptScore W2002169529C203014093 @default.
• W2002169529 hasConceptScore W2002169529C2778105408 @default.
• W2002169529 hasConceptScore W2002169529C71924100 @default.
• W2002169529 hasIssue "Supplement 5" @default.
• W2002169529 hasLocation W20021695291 @default.
• W2002169529 hasOpenAccess W2002169529 @default.
• W2002169529 hasPrimaryLocation W20021695291 @default.
• W2002169529 hasRelatedWork W1506200166 @default.
• W2002169529 hasRelatedWork W1995515455 @default.
• W2002169529 hasRelatedWork W2068377708 @default.
• W2002169529 hasRelatedWork W2080531066 @default.
• W2002169529 hasRelatedWork W2324954285 @default.
• W2002169529 hasRelatedWork W2748952813 @default.
• W2002169529 hasRelatedWork W2899084033 @default.
• W2002169529 hasRelatedWork W3031052312 @default.
• W2002169529 hasRelatedWork W3032375762 @default.
• W2002169529 hasRelatedWork W3108674512 @default.
• W2002169529 hasVolume "48" @default.
• W2002169529 isParatext "false" @default.
• W2002169529 isRetracted "false" @default.
• W2002169529 magId "2002169529" @default.
• W2002169529 workType "article" @default.